| Item type |
文献 / Documents(1) |
| 公開日 |
2019-08-30 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.3892/ijo.2012.1544 |
|
|
言語 |
ja |
|
|
関連名称 |
10.3892/ijo.2012.1544 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Antitumor efficacy of sequential treatment with docetaxel and 5-fluorouracil against human oral cancer cells |
|
言語 |
en |
| タイトル別表記 |
|
|
その他のタイトル |
ANTI-TUMOR EFFICACY OF DOCETAXEL AND 5-FLUOROURACIL |
|
言語 |
en |
| 著者 |
玉谷, 哲也
Ferdous, Tarannum
髙丸, 菜都美
ハラ, カナエ
キノウチ, マコト
栗林, 伸行
大江, 剛
内田, 大亮
永井, 宏和
藤澤, 健司
宮本, 洋二
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Docetaxel (DOC) and 5-fluorouracil (5-FU) are important anticancer agents widely used in the treatment of a variety of cancers including oral squamous cell carcinoma (OSCC). The purpose of this study was to determine the antitumor efficacy of the sequential administration of DOC and 5-FU against OSCC cells (B88 and CAL27 cells) in vitro and in vivo. In in vitro growth inhibition assays, sequential treatment with DOC followed by 5-FU was more effective in inhibiting cancer cell growth than 5-FU followed by DOC, single treatment with DOC or 5-FU, or combined treatment with DOC and 5-FU. Furthermore, DOC followed by 5-FU significantly inhibited tumor growth in vivo compared to 5-FU followed by DOC. To understand the mechanisms underlying the enhanced growth inhibitory effect of the administration sequence, DOC followed by 5-FU, we examined the expression of 5-FU metabolic enzymes such as thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and orotate phosphoribosyl transferase (OPRT), which were known to regulate the antitumor effect of 5-FU, by real-time RT-PCR and western blot analysis. Downregulation of TS and DPD expression and upregulation of OPRT expression were induced by DOC treatment, suggesting that DOC enhanced the efficacy of 5-FU by altering the expression of its metabolic enzymes. These results indicate that sequential treatment with DOC followed by 5-FU could be a promising therapeutic strategy for oral cancer. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
oral squamous cell carcinoma |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
5-fluorouracil |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
docetaxel |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
sequential treatment |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
5-fluorouracil metabolic enzymes |
| 書誌情報 |
en : International Journal of Oncology
巻 41,
号 3,
p. 1148-1156,
発行日 2012-07-04
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
10196439 |
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
17912423 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA10992511 |
| 出版者 |
|
|
出版者 |
Spandidos Publications |
|
言語 |
en |
| EID |
|
|
識別子 |
259867 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
ijo_41_3_1148.pdf (837 KB)
